ArticleThe Journal of clinical investigation2022
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment.
Article in The Journal of clinical investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Local gene editing of fibroblasts in tumors reveals a new cancer-associated fibroblast state.The Journal of experimental medicine · 2026Article
- Interleukin-11 promotes lung adenocarcinoma tumourigenesis and immune evasion.Clinical and translational medicine · 2025Article
- Enhancing antitumor immunity: the role of immune checkpoint inhibitors, anti-angiogenic therapy, and macrophage reprogramming.Frontiers in oncology · 2025Review
- Toll-Like receptor 3-mediated interferon-β production is suppressed by oncostatin m and a broader epithelial-mesenchymal transition program.Breast cancer research : BCR · 2024Article
- Oncostatin M receptor-dependent signaling assessed by RNA sequencing in mouse hematopoietic stem cells.Scientific data · 2024Article
- Prioritizing cervical cancer candidate genes using chaos game and fractal-based time series approach.Theory in biosciences = Theorie in den Biowissenschaften · 2024Article
- Article
- Blocking Oncostatin M receptor abrogates STAT3 mediated integrin signaling and overcomes chemoresistance in ovarian cancer.NPJ precision oncology · 2024Article
- Downregulation of IRF8 in alveolar macrophages by G-CSF promotes metastatic tumor progression.iScience · 2024Article
- Unveiling the contribution of tumor-associated macrophages in driving epithelial-mesenchymal transition: a review of mechanisms and therapeutic Strategies.Frontiers in pharmacology · 2024Review
- Characterization of anbioRxiv : the preprint server for biology · 2023Article
- Involvement in Tumorigenesis and Clinical Significance of CXCL1 in Reproductive Cancers: Breast Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer and Prostate Cancer.International journal of molecular sciences · 2023Review
- OSM May Serve as a Biomarker of Poor Prognosis in Clear Cell Renal Cell Carcinoma and Promote Tumor Cell Invasion and Migration.International journal of genomics · 2023Article
- Activation of OSM-STAT3 Epigenetically Regulates Tumor-Promoting Transcriptional Programs in Cervical Cancer.Cancers · 2022Article
- Review
Corrections and comments
- Erratum for
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.